Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61F-013/00
A61K-009/00
A61K-009/70
출원번호
US-0775484
(2007-07-10)
등록번호
US-8603514
(2013-12-10)
발명자
/ 주소
Yang, Robert K.
Fuisz, Richard C.
Myers, Garry L.
Fuisz, Joseph M.
출원인 / 주소
MonoSol RX, LLC
대리인 / 주소
Hoffmann & Baron, LLP
인용정보
피인용 횟수 :
23인용 특허 :
126
초록▼
The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may
The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.
대표청구항▼
1. A drug delivery composition comprising: (i) a cast film comprising a flowable water-soluble or water swellable film-forming matrix comprising one or more substantially water soluble or water swellable polymers; and a desired amount of at least one active;wherein said matrix has a viscosity suffic
1. A drug delivery composition comprising: (i) a cast film comprising a flowable water-soluble or water swellable film-forming matrix comprising one or more substantially water soluble or water swellable polymers; and a desired amount of at least one active;wherein said matrix has a viscosity sufficient to aid in substantially maintaining non-self-aggregating uniformity of the active in the matrix;(ii) a particulate active substantially uniformly stationed in the matrix; and(iii) a taste-masking agent coated or intimately associated with said particulate to provide taste-masking of the active;wherein the combined particulate and taste-masking agent have a particle size of 200 microns or less and said flowable water-soluble or water swellable film-forming matrix is capable of being dried without loss of substantial uniformity in the stationing of said particulate active therein; andwherein the uniformity subsequent to casting and drying of the matrix is measured by substantially equally sized individual unit doses which do not vary by more than 10% of said desired amount of said at least one active. 2. The drug delivery composition of claim 1, wherein the size of said combined particulate and taste-masking agent have a particle size of 150 microns or less. 3. The drug delivery composition of claim 1, wherein the size of said combined particulate and taste-masking agent have a particle size of 100 microns or less. 4. The drug delivery composition of claim 1, wherein said taste-masking agent is a thin film coating over portions of said active. 5. The drug delivery composition of claim 1, wherein the taste-masking agent is a polymer. 6. The drug delivery composition of claim 1, wherein the taste-masking agent is a water-soluble polymer. 7. The drug delivery composition of claim 6, wherein said water-soluble polymer has an average molecular weight of equal to or greater than about 40,000. 8. The drug delivery composition of claim 1, wherein the taste-masking agent is selected from the group consisting of acrylic polymers, cellulosic polymers, vinyl polymers, crown ethers, hydrogenated oils and waxes, and combinations thereof. 9. The drug delivery composition of claim 1, wherein said variation of drug content is less than 5% by weight per film dosage unit. 10. The drug delivery composition of claim 1, wherein said variation of drug content is less than 2% by weight per film dosage unit. 11. The drug delivery composition of claim 1, wherein said variation of drug content is less than 0.5% by weight per film dosage unit. 12. The drug delivery composition of claim 1, wherein said taste-masking agent is present in the amount of about 15-80% by weight of the particle. 13. The drug delivery composition of claim 1, wherein said taste-masking agent is present in the amount of about 20-60% by weight of the particle. 14. The drug delivery composition of claim 1, wherein said taste-masking agent is present in the amount of about 25-35% by weight of the particle. 15. The drug delivery composition of claim 1, wherein said active is selected from the group consisting of antimicrobial agents, non-steroidal anti-inflammatory drugs, anti-tussives, decongestants, antihistamines, expectorants, anti-diarrheals, H2 antagonists, proton pump inhibitors, general non-selective CNS depressants, general non-selective CNS stimulants, selective CNS functional modifiers, anti-parkinsonism drugs, narcotics, analgesics, erectile dysfunction therapies, anti-pyretics, psychopharmacological drugs and combinations thereof. 16. A thin film drug delivery composition comprising: (a) a cast film comprising an edible water-soluble or water swellable film-forming matrix comprising at least one water-soluble or water swellable polymer comprising polyethylene oxide alone or in combination with a hydrophilic cellulosic polymer; and a desired amount of at least one active;wherein said matrix has a viscosity sufficient to aid in substantially maintaining non-self-aggregating uniformity of the active in the matrix;and(b) a coated particulate active component substantially uniformly stationed in the matrix; wherein the coating on the particulate active component is a taste-masking agent, andwherein the active component is substantially uniformly distributed in the film composition; andwherein the uniformity subsequent to casting and drying of the matrix is measured by substantially equally sized individual unit doses which do not vary by more than 10% of said desired amount of said at least one active. 17. The drug delivery composition of claim 16, wherein said thin film drug delivery composition is extruded. 18. The drug delivery composition of claim 16, wherein the taste-masking agent is a thin film coating over the particulate active component. 19. The drug delivery composition of claim 16, wherein the taste-masking agent is a water-soluble polymer. 20. The drug delivery composition of claim 16, wherein the composition is free of added plasticizers, surfactants, or polyalcohols. 21. The drug delivery composition of claim 1, wherein the taste-masking agent is selected from the group consisting of carboxymethyl cellulose; methyl cellulose; ethyl cellulose; hydroxyl methyl cellulose; hydroxyethyl cellulose; hydroxypropyl cellulose; hydroxypropylmethyl cellulose; hydroxymethylpropyl cellulose; gum arabic; xanthan gum; tragacanth; acacia; carageenan; guar gum; locust bean gum; pectin; alginates; gelatinized, modified or unmodified starch; polyvinyl alcohol; polyacrylic acid; polyvinyl pyrrolidone; poly(meth)acrylate; poly(meth)copolymers; dextrin; dextran; proteins; whey protein isolate; casein; levin; collagen; chitin; chitosin; polydextrose and combinations thereof. 22. The drug delivery composition of claim 1, wherein said active is selected from the group consisting of ace-inhibitors, antianginal drugs, anti-arrhythmias, anti-asthmatics, anti-cholesterolemics, analgesics, anesthetics, anti-convulsants, anti-depressants, anti-diabetic agents, anti-diarrhea preparations, antidotes, anti-histamines, anti-hypertensive drugs, anti-inflammatory agents, anti-lipid agents, anti-manics, anti-nauseants, anti-stroke agents, anti-thyroid preparations, anti-tumor drugs, anti-viral agents, acne drugs, alkaloids, amino acid preparations, anti-tussives, anti-uricemic drugs, anti-viral drugs, anabolic preparations, systemic and non-systemic anti-infective agents, anti-neoplastics, anti-parkinsonian agents, anti-rheumatic agents, appetite stimulants, biological response modifiers, blood modifiers, bone metabolism regulators, cardiovascular agents, central nervous system stimulates, cholinesterase inhibitors, contraceptives, decongestants, dietary supplements, dopamine receptor agonists, endometriosis management agents, enzymes, erectile dysfunction therapies, fertility agents, gastrointestinal agents, homeopathic remedies, hormones, hypercalcemia and hypocalcemia management agents, immunomodulators, immunosuppressives, migraine preparations, motion sickness treatments, muscle relaxants, obesity management agents, osteoporosis preparations, oxytocics, parasympatholytics, parasympathomimetics, prostaglandins, psychotherapeutic agents, respiratory agents, sedatives, smoking cessation aids, sympatholytics, tremor preparations, urinary tract agents, vasodilators, laxatives, antacids, ion exchange resins, anti-pyretics, appetite suppressants, expectorants, anti-anxiety agents, anti-ulcer agents, anti-inflammatory substances, coronary dilators, cerebral dilators, peripheral vasodilators, psycho-tropics, stimulants, anti-hypertensive drugs, vasoconstrictors, migraine treatments, antibiotics, tranquilizers, anti-psychotics, anti-tumor drugs, anti-coagulants, anti-thrombotic drugs, hypnotics, anti-emetics, anti-nauseants, anti-convulsants, neuromuscular drugs, hyper- and hypo-glycemic agents, thyroid and anti-thyroid preparations, diuretics, anti-spasmodics, terine relaxants, anti-obesity drugs, erythropoietic drugs, anti-asthmatics, cough suppressants, mucolytics, DNA and genetic modifying drugs, and combinations thereof. 23. The drug delivery composition of claim 1, wherein the film forming matrix has the viscosity in an amount sufficient to substantially prevent an active from settling out during mixing or coating. 24. The drug delivery composition of claim 1, wherein said taste-masking agent is selected from the group consisting of flavors, sweeteners, flavor enhancers, and combinations thereof. 25. The drug delivery composition of claim 1, wherein said active is an opiate or opiate derivative. 26. The drug delivery composition of claim 16, wherein said taste-masking agent is selected from the group consisting of flavors, sweeteners, flavor enhancers, and combinations thereof. 27. The drug delivery composition of claim 16, wherein said active is an opiate or opiate derivative. 28. A drug delivery composition comprising: (i) a cast film comprising a flowable water-soluble or water swellable film-forming matrix comprising one or more substantially water soluble or water swellable polymers; and a desired amount of at least one active;wherein said matrix has a viscosity sufficient to aid in substantially maintaining non-self-aggregating uniformity of the active in the matrix;(ii) a particulate active substantially uniformly stationed in the matrix; and(iii) a taste-masking agent coated or intimately associated with said particulate to provide taste-masking of the active;wherein the combined particulate and taste-masking agent have a particle size of 200 microns or less and said flowable water-soluble or water swellable film-forming matrix is capable of being dried without loss of substantial uniformity in the stationing of said particulate active therein;wherein the uniformity subsequent to casting and drying of the matrix is measured by substantially equally sized individual unit doses which do not vary by more than 10% of said desired amount of said at least one active; andwherein the coated particulate active has a shape selected from the group consisting of spherically shaped particles, ellipsoidally shaped particles, irregularly shaped particles, and combinations thereof. 29. The drug delivery composition of claim 28, wherein the size of said combined particulate and taste-masking agent have a particle size of 150 microns or less. 30. The drug delivery composition of claim 28, wherein the size of said combined particulate and taste-masking agent have a particle size of 100 microns or less. 31. The drug delivery composition of claim 28, wherein said taste-masking agent is a thin film coating over portions of said active. 32. The drug delivery composition of claim 28, wherein the taste-masking agent is a polymer. 33. The drug delivery composition of claim 28, wherein the taste-masking agent is a water-soluble polymer. 34. The drug delivery composition of claim 33, wherein said water-soluble polymer has an average molecular weight of equal to or greater than about 40,000. 35. The drug delivery composition of claim 28, wherein the taste-masking agent is selected from the group consisting of acrylic polymers, cellulosic polymers, vinyl polymers, crown ethers, hydrogenated oils and waxes, and combinations thereof. 36. The drug delivery composition of claim 28, wherein said variation of drug content is less than 5% by weight per film dosage unit. 37. The drug delivery composition of claim 28, wherein said variation of drug content is less than 2% by weight per film dosage unit. 38. The drug delivery composition of claim 28, wherein said variation of drug content is less than 0.5% by weight per film dosage unit. 39. The drug delivery composition of claim 28, wherein said taste-masking agent is present in the amount of about 15-80% by weight of the particle. 40. The drug delivery composition of claim 28, wherein said taste-masking agent is present in the amount of about 20-60% by weight of the particle. 41. The drug delivery composition of claim 28, wherein said taste-masking agent is present in the amount of about 25-35% by weight of the particle. 42. The drug delivery composition of claim 28, wherein said active is selected from the group consisting of antimicrobial agents, non-steroidal anti-inflammatory drugs, anti-tussives, decongestants, antihistamines, expectorants, anti-diarrheals, H2 antagonists, proton pump inhibitors, general non-selective CNS depressants, general non-selective CNS stimulants, selective CNS functional modifiers, anti-parkinsonism drugs, narcotics, analgesics, erectile dysfunction therapies, anti-pyretics, psychopharmacological drugs and combinations thereof. 43. The drug delivery composition of claim 28, wherein the taste-masking agent is selected from the group consisting of carboxymethyl cellulose; methyl cellulose; ethyl cellulose; hydroxyl methyl cellulose; hydroxyethyl cellulose; hydroxypropyl cellulose; hydroxypropylmethyl cellulose; hydroxymethylpropyl cellulose; gum arabic; xanthan gum; tragacanth; acacia; carageenan; guar gum; locust bean gum; pectin; alginates; gelatinized, modified or unmodified starch; polyvinyl alcohol; polyacrylic acid; polyvinyl pyrrolidone; poly(meth)acrylate; poly(meth)copolymers; dextrin; dextran; proteins; whey protein isolate; casein; levin; collagen; chitin; chitosin; polydextrose and combinations thereof. 44. The drug delivery composition of claim 28, wherein said active is selected from the group consisting of ace-inhibitors, antianginal drugs, anti-arrhythmias, anti-asthmatics, anti-cholesterolemics, analgesics, anesthetics, anti-convulsants, anti-depressants, anti-diabetic agents, anti-diarrhea preparations, antidotes, anti-histamines, anti-hypertensive drugs, anti-inflammatory agents, anti-lipid agents, anti-manics, anti-nauseants, anti-stroke agents, anti-thyroid preparations, anti-tumor drugs, anti-viral agents, acne drugs, alkaloids, amino acid preparations, anti-tussives, anti-uricemic drugs, anti-viral drugs, anabolic preparations, systemic and non-systemic anti-infective agents, anti-neoplastics, anti-parkinsonian agents, anti-rheumatic agents, appetite stimulants, biological response modifiers, blood modifiers, bone metabolism regulators, cardiovascular agents, central nervous system stimulates, cholinesterase inhibitors, contraceptives, decongestants, dietary supplements, dopamine receptor agonists, endometriosis management agents, enzymes, erectile dysfunction therapies, fertility agents, gastrointestinal agents, homeopathic remedies, hormones, hypercalcemia and hypocalcemia management agents, immunomodulators, immunosuppressives, migraine preparations, motion sickness treatments, muscle relaxants, obesity management agents, osteoporosis preparations, oxytocics, parasympatholytics, parasympathomimetics, prostaglandins, psychotherapeutic agents, respiratory agents, sedatives, smoking cessation aids, sympatholytics, tremor preparations, urinary tract agents, vasodilators, laxatives, antacids, ion exchange resins, anti-pyretics, appetite suppressants, expectorants, anti-anxiety agents, anti-ulcer agents, anti-inflammatory substances, coronary dilators, cerebral dilators, peripheral vasodilators, psycho-tropics, stimulants, anti-hypertensive drugs, vasoconstrictors, migraine treatments, antibiotics, tranquilizers, anti-psychotics, anti-tumor drugs, anti-coagulants, anti-thrombotic drugs, hypnotics, anti-emetics, anti-nauseants, anti-convulsants, neuromuscular drugs, hyper- and hypo-glycemic agents, thyroid and anti-thyroid preparations, diuretics, anti-spasmodics, terine relaxants, anti-obesity drugs, erythropoietic drugs, anti-asthmatics, cough suppressants, mucolytics, DNA and genetic modifying drugs, and combinations thereof. 45. The drug delivery composition of claim 28, wherein the film forming matrix has the viscosity in an amount sufficient to substantially prevent an active from settling out during mixing or coating. 46. The drug delivery composition of claim 28, wherein said taste-masking agent is selected from the group consisting of flavors, sweeteners, flavor enhancers, and combinations thereof. 47. The drug delivery composition of claim 28, wherein said active is an opiate or opiate derivative. 48. A thin film drug delivery composition comprising: (a) a cast film comprising an edible water-soluble or water swellable film-forming matrix comprising at least one water-soluble or water swellable polymer comprising polyethylene oxide alone or in combination with a hydrophilic cellulosic polymer; and a desired amount of at least one active;wherein said matrix has a viscosity sufficient to aid in substantially maintaining non-self-aggregating uniformity of the active in the matrix;and(b) a coated particulate active component substantially uniformly stationed in the matrix; wherein the coating on the particulate active component is a taste-masking agent, andwherein the active component is substantially uniformly distributed in the film composition;wherein the uniformity subsequent to casting and drying of the matrix is measured by substantially equally sized individual unit doses which do not vary by more than 10% of said desired amount of said at least one active; andwherein the at least one water-soluble polymer comprises about 20% to about 100% by weight polyethylene oxide. 49. The drug delivery composition of claim 48, wherein said thin film drug delivery composition is extruded. 50. The drug delivery composition of claim 48, wherein the taste-masking agent is a thin film coating over the particulate active component. 51. The drug delivery composition of claim 48, wherein the taste-masking agent is a water-soluble polymer. 52. The drug delivery composition of claim 48, wherein the composition is free of added plasticizers, surfactants, or polyalcohols. 53. The drug delivery composition of claim 48, wherein said taste-masking agent is selected from the group consisting of flavors, sweeteners, flavor enhancers, and combinations thereof. 54. The drug delivery composition of claim 48, wherein said active is an opiate or opiate derivative. 55. A thin film drug delivery composition comprising: (a) a cast film comprising an edible water-soluble or water swellable film-forming matrix comprising at least one water-soluble or water swellable polymer comprising polyethylene oxide alone or in combination with a hydrophilic cellulosic polymer; and a desired amount of at least one active;wherein said matrix has a viscosity sufficient to aid in substantially maintaining non-self-aggregating uniformity of the active in the matrix;and(b) a coated particulate active component substantially uniformly stationed in the matrix; wherein the coating on the particulate active component is a taste-masking agent, andwherein the active component is substantially uniformly distributed in the film composition;wherein the uniformity subsequent to casting and drying of the matrix is measured by substantially equally sized individual unit doses which do not vary by more than 10% of said desired amount of said at least one active; andwherein the at least one water-soluble polymer comprises a hydrophilic cellulosic polymer in a ratio of up to about 4:1 with polyethylene oxide. 56. The drug delivery composition of claim 55, wherein said thin film drug delivery composition is extruded. 57. The drug delivery composition of claim 55, wherein the taste-masking agent is a thin film coating over the particulate active component. 58. The drug delivery composition of claim 55, wherein the taste-masking agent is a water-soluble polymer. 59. The drug delivery composition of claim 55, wherein the composition is free of added plasticizers, surfactants, or polyalcohols. 60. The drug delivery composition of claim 55, wherein said taste-masking agent is selected from the group consisting of flavors, sweeteners, flavor enhancers, and combinations thereof. 61. The drug delivery composition of claim 55, wherein said active is an opiate or opiate derivative. 62. A drug delivery composition comprising: (i) a cast film comprising a flowable water-soluble or water swellable film-forming matrix comprising one or more substantially water soluble or water swellable polymers; and a desired amount of at least one active;wherein said matrix has a viscosity sufficient to aid in substantially maintaining non-self-aggregating uniformity of the active in the matrix;(ii) a particulate active substantially uniformly stationed in the matrix; and(iii) a taste-masking agent selected from the group consisting of flavors, sweeteners, flavor enhancers, and combinations thereof to provide taste-masking of the active;wherein the particulate active has a particle size of 200 microns or less and said flowable water-soluble or water swellable film-forming matrix is capable of being dried without loss of substantial uniformity in the stationing of said particulate active therein; andwherein the uniformity subsequent to casting and drying of the matrix is measured by substantially equally sized individual unit doses which do not vary by more than 10% of said desired amount of said at least one active. 63. The drug delivery composition of claim 62, wherein the particulate active has a particle size of 150 microns or less. 64. The drug delivery composition of claim 62, wherein the particulate active has a particle size of 100 microns or less. 65. The drug delivery composition of claim 62, wherein said variation of drug content is less than 5% by weight per film dosage unit. 66. The drug delivery composition of claim 62, wherein said variation of drug content is less than 2% by weight per film dosage unit. 67. The drug delivery composition of claim 62, wherein said variation of drug content is less than 0.5% by weight per film dosage unit. 68. The drug delivery composition of claim 62, wherein the particulate active has a shape selected from the group consisting of spherically shaped particles, ellipsoidally shaped particles, irregularly shaped particles, and combinations thereof. 69. The drug delivery composition of claim 62, wherein said taste-masking agent is present in the amount of about 0.1-30% by weight of the drug delivery composition. 70. The drug delivery composition of claim 62, wherein said taste-masking agent is present in the amount of about 0.01-10% by weight of the drug delivery composition. 71. The drug delivery composition of claim 62, wherein said active is selected from the group consisting of antimicrobial agents, non-steroidal anti-inflammatory drugs, anti-tussives, decongestants, antihistamines, expectorants, anti-diarrheals, H2 antagonists, proton pump inhibitors, general non-selective CNS depressants, general non-selective CNS stimulants, selective CNS functional modifiers, anti-parkinsonism drugs, narcotics, analgesics, erectile dysfunction therapies, anti-pyretics, psychopharmacological drugs and combinations thereof. 72. The drug delivery composition of claim 62, wherein the film forming matrix has the viscosity in an amount sufficient to substantially prevent an active from settling out during mixing or coating. 73. The drug delivery composition of claim 62, wherein said active is an opiate or opiate derivative. 74. The drug delivery composition of claim 73, wherein said taste masking agent is peppermint oil. 75. The drug delivery composition of claim 1, wherein said active is an opiate or opiate derivative and said taste masking agent is selected from the group consisting of flavors, sweeteners, flavor enhancers, and combinations thereof. 76. The drug delivery composition of claim 75, wherein said taste masking agent is peppermint oil.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (126)
Altwirth Oskar (Oberach 37 A-4950 Altheim ATX), Adherent insert for artificial teeth and process of manufacturing the insert.
Babaian Eduard A. (Moscow SUX) Gerasimova Galina A. (Moscow SUX) Davydov Anatoly B. (Moscow SUX) Utyamyshev Rustam I. (Moscow SUX) Khromov Gennady L. (Moscow SUX) Metelitsa Vladimir I. (Moscow SUX) V, Antianginal film and method of treating ischemic heart disease.
Strobush Brian L. ; Ludemann Thomas J. ; Yonkoski Roger K., Apparatus and method for drying a coating on a substrate employing multiple drying subzones.
Hijiya Hiromi (Okayama JPX) Miyake Toshio (Okayama JPX), Association complex comprising pullulan and polyethylene glycol, and preparation and uses of the same.
Rel Bernhard (Knigstein/Taunus DEX) Petri Walter (Niedernhausen/Taunus DEX), Base for mucosal and denture adhesive pastes, a process for the preparation thereof, and pastes having this base.
Schiraldi Michael T. (East Brunswick NJ) Perl Martin M. (Brooklyn NY) Rubin Howard (Rockaway NJ), Bioadhesive extruded film for intra-oral drug delivery and process.
Schiraldi Michael T. (East Brunswick NJ) Perl Martin M. (Brooklyn NY) Rubin Howard (Rockaway NJ), Bioadhesive extruded film for intra-oral drug delivery and process.
Michael A. Repka ; Staci L. Repka ; James W. McGinity, Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof.
Fischel-Ghodsian Fariba (2122 Century Park La. ; #104 Los Angeles CA 90067), Device for controlled release of vaporous medications through nasal route.
Hymes Alan C. (Minnetonka MN) Ong Lincoln T. (Minnetonka MN) Persons Garry R. (Edina MN), Drug dispensing device for transdermal delivery of medicaments.
Eury Robert P. (Cupertino CA) Garguilo Darlene (Fremont CA) Villareal Plaridel (San Jose CA), Drug loaded polymeric material and method of manufacture.
Mehra Dev K. ; Ramireddy Chittamuru ; Tang Li-Juan ; Porter Stuart C., Enteric film coating compositions, method of coating therewith, and coated forms.
Bess,William S.; Kulkarni,Neema; Ambike,Suhas H.; Ramsay,Michael P., Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1.
Jevne Allan H. (Anoka MN) Vegoe Brett R. (Brooklyn Park MN) Holmblad Carolann M. (Cambridge MN) Cahalan Patrick T. (Champlin MN), Hydrophilic pressure sensitive biomedical adhesive composition.
Broberg Berndt F. J. (Sdertlje SEX) Evers Hans C. A. (Sdertlje SEX), Local anesthetic mixture for topical application and method for obtaining local anesthesia.
Leusner Bernd (Leverkusen DEX) Heiss Rdiger (Grefrath DEX) Pelster Bernd (St. Augustin DEX) Fischer Wolfgang (Bergisch Gladbach DEX) Ohm Ulrich (Odenthal DEX), Medicaments for the region of the oral cavity.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Kizawa Hidenori (Tokyo JPX) Fujiyama Norimasa (Tokyo JPX) Kobayashi Jitsuo (Kanagawa JPX) Ito Akinori (Niigata JPX), Mucous membrane-adhering film preparation and process for its preparation.
Sorrentino James V. (Wilton CT) Kelleher William J. (Storrs CT) Moye Jeanne O. (Fairfield CT), Pharmaceutical compositions containing dyclonine HC1 and phenol.
Santus Giancarlo (Milan ITX) Bottoni Giuseppe (Bergamo ITX) Sala Giovanni (Verona ITX), Pharmaceutical controlled-release composition with bioadhesive properties.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Noguchi Toshihide (Tokyo JPX) Izumizawa Katsunori (Yokohama JPX) Kinoshita ; deceased Shiro (late of Tokyo JPX by Kimiko Kinoshita ; Atsuhiro Kinosh, Pharmaceutical preparation for remedy of periodontal disease and process for production thereof.
Vert Michel (Mont-Saint-Aignan FRX) Mauduit Jacques (Bacqueville En Caux FRX) Bukh Niels (Hellerup DKX), Polylactic acid-based implant susceptible of bioresorption containing and antibiotic.
Schmidt Wolfgang (Reembroden 44 D-2000 Hamburg 63 DEX), Process for producing an administration or dosage form for drugs, reagents or other active ingredients.
Horstmann Michael (Neuwied DEX) Laux Wolfgang (Dietz DEX) Hungerbach Stefan (Nortershausen DEX), Rapidly disintegrating sheet-like presentations of multiple dosage units.
Chang Yunik (Lakewood NJ) Patel Dinesh C. (Murray UT), Skin penetration enhancement using free base and acid addition salt combinations of active agents.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Koganei JPX), Slow-releasing medical preparation to be administered by adhering to a wet mucous surface.
Wheatley Margaret A. (Arlington MA) Langer Robert S. (Somerville MA) Eisen Herman N. (Waban MA), System for delayed and pulsed release of biologically active substances.
AF Ekenstam Bo T. (Box 721 Hjlteby SEX S-440 74) Aberg Gunnar A. K. (Utsiktsvgen 7 Falkenberg SEX S-311 00), Therapeutically active, substituted piperidines and pyrrolidines therapeutic compositions thereof and methods of use the.
Heiber Sonia J. (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT) Dave Sirish C. (Salt Lake City UT), Transmucosal delivery of macromolecular drugs.
Biegajski James E. (Foster City CA) Venkatraman Subbu S. (Palo Alto CA) Scott Ann M. (Mountain View CA), Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavi.
Thompson, Edwin R.; Thompson, Eric R.; Myslinski, Nicholas R.; Kemeny, Steven F.; Hart, Matthew N., Immediate release abuse deterrent liquid fill dosage form.
Fuisz, Richard C.; Fuisz, Joseph M., Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent.
Yang, Robert K.; Fuisz, Richard C.; Myers, Garry L.; Fuisz, Joseph M., Uniform films for rapid dissolve dosage form incorporating taste-masking compositions.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.